Keros Therapeutics director proposes $5.52K share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Keros Therapeutics, Inc. (KROS) reports a proposed sale by director Charles W. Newton of 551 common shares, with an aggregate market value of $5,521.02 and an approximate sale date of November 17, 2026. The shares were acquired from the issuer as restricted stock units on November 15, 2026; the notice gives March 12, 2026, as the adoption or instruction date for a Rule 10b5-1 plan.
Newton also reported a prior sale of 551 common shares on August 18, 2026, for gross proceeds of $5,675.08.
Key Figures
Key Terms
restricted stock units financial
Rule 10b5-1 regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.